1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Linhui Peng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC Infusional mFOLFOX7 plus Camrelizumab and apatinib, Camrelizumab and apatinib - Hepato Cellular Carcinoma (HCC), Chemotherapy Effect | Phase 3 | Recruiting | Linhui Peng | 326 | 2025-10-31 | 2025-12-16 |
apatinib (1) · camrelizumab (1)
China (1)